During Movember, Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

While prostate cancer affects about 1 in 8 men, when it's caught early, there's a 99% survival rate, according to Cancer.org.

ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...

Prostate cancer is the most common cancer in men, with an estimated one in eight Canadian men expected to be diagnosed in ...

According to the 2019 National Cancer Registry the lifetime risk for prostate cancer in South Africa is 1 in every 15 man.

Intravenous; mCRPC: Metastatic castration-resistant prostate ... Androgen deprivation is the mainstay of therapy of advanced prostate cancer treatment, but the cure rate is low and patients ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Sep. 23, 2024 — A new preclinical model using CRISPR, an advanced technology ... Aug. 20, 2024 — Men with metastatic castration-resistant prostate cancer should be treated primarily with ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...